EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

Efficacy and Safety of Prophylaxis With a Plasma‐Derived von Willebrand Factor/Factor VIII Concentrate (Wilate) in Patients With Type 3 von Willebrand Disease—A WIL‐31 Study Sub‐Analysis

Claudia Djambas Khayat, Leonid Dubey, Adlette Inati, Toshko Lissitchkov, Dzmitry Novik, Elina Peteva, Robert F Sidonio iD, Ali T Taher, Kateryna V Vilchevska, Vladimir Vdovin, Ana Boban

European Journal of Haematology · 2026

DOI: 10.1111/ejh.70117 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Claudia Djambas Khayat und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hotel Dieu de France Hospital, Saint Joseph University, Beirut, Lebanon. Hauptthemen laut MEDLINE: Factor VIII, von Willebrand Disease, Type 3, von Willebrand Factor. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Octapharma AG, Octapharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The WIL‐31 study demonstrated efficacy and safety of prophylaxis with the plasma‐derived von Willebrand factor/factor VIII concentrate wilate in von Willebrand disease (VWD) of all types and was the only prospective study with an on‐demand run‐in study as an intra‐individual comparator. This subgroup analysis examines the efficacy of wilate prophylaxis in patients with type 3 VWD in WIL‐31.

Methods

Patients received 20–40 IU/kg wilate prophylaxis 2–3 times weekly for 12 months.

Results

Twenty‐two patients in WIL‐31 had type 3 VWD. Mean total annualized bleeding rate (ABRs) during on‐demand versus prophylaxis was 37.1 versus 5.2 (86% reduction). During prophylaxis, 115 bleeds occurred, most (95%) of which were minor; the most common bleeding site was the nose (40% of bleeds). Mean overall spontaneous ABRs during on‐demand versus prophylaxis were 26.5 versus 2.8 (89% reduction); mean treated spontaneous ABRs were 20.3 versus 1.4, respectively (93% reduction). ABRs were reduced further during the second 6 months of prophylaxis versus the first 6 months. Results were consistent in subgroups by age. No serious adverse events related to study treatment and no thrombotic events were observed.

Conclusions

Prophylaxis with wilate was effective and well tolerated in patients with type 3 VWD, in all age groups. Trial Registration: NCT04052698; https://clinicaltrials.gov/study/NCT04052698

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor VIIIvon Willebrand Disease, Type 3von Willebrand FactorAdolescentAdultAgedChildChild, PreschoolFemaleHumansInfantMaleMiddle AgedYoung AdultHemorrhageTreatment OutcomeDrug Combinations

Stichwörter der Autor:innen

hemostaticsprevention & controltype 3 von Willebrand diseasevon Willebrand diseasevon Willebrand factor

Substanzen

Factor VIIIfactor VIII, von Willebrand factor drug combinationvon Willebrand FactorDrug Combinations

Autor:innen und Institutionen

  • Hotel Dieu de France Hospital, Saint Joseph University, Beirut, Lebanon.
  • Communal Nonprofit Enterprise "Western Ukrainian Specialized Children's Medical Center" of Lviv Regional Council, Lviv, Ukraine.
  • NINI Hospital and LAU Gilbert and Rose-Marie Chaghoury School of Medicine, Byblos and Beirut, Lebanon.
  • Department of Chemotherapy, Hemotherapy and Hereditary Blood Diseases at Clinical Hematology Clinic, Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria.
  • Government Agency "Republican Research Center for Radiation Medicine and Human Ecology", Gomel, Belarus.
  • Pediatric Clinic of Haematology and Oncology, University Hospital St. Marina-Varna, Varna, Bulgaria.

ORCID-Profile: Robert F Sidonio

Förderung

  • Octapharma AG
  • Octapharma

Zitieren

APA

Djambas Khayat, C., Dubey, L., Inati, A., Lissitchkov, T., Novik, D., Peteva, E., Sidonio, R. F., Taher, A. T., Vilchevska, K. V., Vdovin, V., & Boban, A. (2026). Efficacy and Safety of Prophylaxis With a Plasma‐Derived von Willebrand Factor/Factor VIII Concentrate (Wilate) in Patients With Type 3 von Willebrand Disease—A WIL‐31 Study Sub‐Analysis. European Journal of Haematology. https://doi.org/10.1111/ejh.70117

Vancouver

Djambas Khayat C, Dubey L, Inati A, Lissitchkov T, Novik D, Peteva E, et al. Efficacy and Safety of Prophylaxis With a Plasma‐Derived von Willebrand Factor/Factor VIII Concentrate (Wilate) in Patients With Type 3 von Willebrand Disease—A WIL‐31 Study Sub‐Analysis. European Journal of Haematology. 2026. doi:10.1111/ejh.70117

BibTeX
@article{DjambasKhayat2026,
  author = {Djambas Khayat, Claudia and Dubey, Leonid and Inati, Adlette and Lissitchkov, Toshko and Novik, Dzmitry and Peteva, Elina and Sidonio, Robert F and Taher, Ali T and Vilchevska, Kateryna V and Vdovin, Vladimir and Boban, Ana},
  title = {Efficacy and Safety of Prophylaxis With a Plasma‐Derived von Willebrand Factor/Factor VIII Concentrate (Wilate) in Patients With Type 3 von Willebrand Disease—A WIL‐31 Study Sub‐Analysis},
  journal = {European Journal of Haematology},
  year = {2026},
  doi = {10.1111/ejh.70117}
}
Kostenlos starten →